{"id":"W4388033279","doi":"10.1177/13524585231205708","title":"Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital; Ottawa Hospital; McGill University; NeuroRx Research (Canada); University of Ottawa; University of Toronto; Montreal Neurological Institute and Hospital","funders":"Academy of Military Medical Sciences; Chugai Pharmaceutical; EMD Serono; Eisai; Deutsche Forschungsgemeinschaft; Genentech; Horizon Therapeutics; TG Therapeutics; H. Lundbeck A/S; BeiGene; Federalno Ministarstvo Obrazovanja i Nauke; European Committee for Treatment and Research in Multiple Sclerosis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Greenwich Biosciences; Alexion Pharmaceuticals; Bundesministerium für Bildung und Forschung; Teva Pharmaceutical Industries; Celgene; Pfizer; Biogen; CSL Behring Foundation for Research and Advancement of Patient Health; Sanofi","keywords":"Tolerability; Dimethyl fumarate; Medicine; Multiple sclerosis; Adverse effect; Relapsing remitting; Clinical endpoint; Confidence interval; Internal medicine; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002666634,0.0006375727,0.001243481,0.0001859818,0.000249191,0.0004647955,0.000341986,0.0005576544,0.0008256194],"category_scores_gemma":[0.001356678,0.0001920209,0.0007014166,0.0002319771,0.0002358626,0.000401298,0.0002262967,0.00104693,0.0002685317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003759776,"about_ca_system_score_gemma":0.0004715992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004880383,"about_ca_topic_score_gemma":0.001364539,"domain_scores_codex":[0.9995327,0.0002400257,0.00004535824,0.00004697362,0.00008395839,0.00005089003],"domain_scores_gemma":[0.9990963,0.0002056905,0.0003152594,0.00005526748,0.0001172415,0.0002102742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5006983,0.023038,0.0794638,0.00179759,0.003801883,0.0007018884,0.0008419348,0.002462311,0.05404991,0.0001985632,0.005756733,0.3271891],"study_design_scores_gemma":[0.2999221,0.4088931,0.2660367,0.0001807491,0.002359081,0.001725975,0.0001741914,0.003131321,0.009850478,0.0002335746,0.00741308,0.00007953806],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943381,0.003758211,0.0002291056,0.000166617,0.00002189555,0.000309038,0.0003927525,0.00003328633,0.0007510873],"genre_scores_gemma":[0.9957024,0.001310033,0.0007105924,0.0004140064,0.00006161713,0.0002493389,0.001101701,0.000009594903,0.000440759],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002666634,"threshold_uncertainty_score":0.0141027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1290231358133592,"score_gpt":0.3116451762617941,"score_spread":0.1826220404484348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}